+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Parkinsons Disease (PD) Drugs Market 2020-2024- Product Image

Global Parkinsons Disease (PD) Drugs Market 2020-2024

  • ID: 5237598
  • Report
  • January 2021
  • Region: Global
  • 120 pages
  • TechNavio

FEATURED COMPANIES

  • AbbVie Inc.
  • Eisai Co. Ltd.
  • GlaxoSmithKline Plc
  • Kyowa Kirin Co. Ltd.
  • Novartis AG
  • UCB SA
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Global Parkinsons Disease (PD) Drugs Market 2020-2024

The publisher has been monitoring the Parkinson's disease (PD) drugs market and it is poised to grow by $ 1.57 bn during 2020-2024, progressing at a CAGR of 6% during the forecast period. The report on Parkinson's disease (PD) drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the new drug launches and strong drug pipeline. In addition, new drug launches is anticipated to boost the growth of the market as well.

The Parkinson's disease (PD) drugs market analysis includes drug class segments and geographical landscapes.

The Parkinson's disease (PD) drugs market is segmented as below:

By Drug Class
  • DA and levodopa-carbidopa
  • MAO inhibitors
  • AChE inhibitors
  • glutamate inhibitors
  • others
By Geographical Landscapes
  • Europe
  • North America
  • Asia
  • ROW
This study identifies the rise in geriatric population as one of the prime reasons driving the Parkinson's disease (PD) drugs market growth during the next few years.

The report on Parkinson's disease (PD) drugs market covers the following areas:
  • Parkinsons disease (PD) drugs market sizing
  • Parkinsons disease (PD) drugs market forecast
  • Parkinsons disease (PD) drugs market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading Parkinson's disease (PD) drugs market vendors that include AbbVie Inc., Amneal Pharmaceuticals Inc., Bausch Health Companies Inc., Boehringer Ingelheim International GmbH, Eisai Co. Ltd., GlaxoSmithKline Plc, Kyowa Kirin Co. Ltd., Novartis AG, Teva Pharmaceutical Industries Ltd., and UCB SA. Also, the Parkinson's disease (PD) drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie Inc.
  • Eisai Co. Ltd.
  • GlaxoSmithKline Plc
  • Kyowa Kirin Co. Ltd.
  • Novartis AG
  • UCB SA
Executive Summary
  • Market Overview
Market Landscape
  • Market ecosystem
  • Market characteristics
  • Value chain analysis
Market Sizing
  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 - 2024
Five Forces Analysis
  • Five forces summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
Market Segmentation by Drug Class
  • Market segments
  • Comparison by drug class
  • DA and levodopa-carbidopa - Market size and forecast 2019-2024
  • MAO inhibitors - Market size and forecast 2019-2024
  • AChE inhibitors - Market size and forecast 2019-2024
  • Glutamate inhibitors - Market size and forecast 2019-2024
  • Others - Market size and forecast 2019-2024
  • Market opportunity by drug class
Customer landscape
  • Overview
Geographic Landscape
  • Geographic segmentation
  • Geographic comparison
  • Europe - Market size and forecast 2019-2024
  • North America - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography
  • Market drivers
  • Market challenges
  • Market trends
Vendor Landscape
  • Competitive scenario
  • Vendor landscape
  • Landscape disruption
Vendor Analysis
  • Vendors covered
  • Market positioning of vendors
  • AbbVie Inc.
  • Amneal Pharmaceuticals Inc.
  • Bausch Health Companies Inc.
  • Boehringer Ingelheim International GmbH
  • Eisai Co. Ltd.
  • GlaxoSmithKline Plc
  • Kyowa Kirin Co. Ltd.
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA
Appendix
  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations
Exhibit
  • Key Finding 1
  • Key Finding 2
  • Key Finding 3
  • Key Finding 5
  • Key Finding 6
  • Key Finding 7
  • Key Finding 8
  • Parent market
  • Market characteristics
  • Offerings of vendors included in the market definition
  • Market segments
  • Global - Market size and forecast 2019 - 2024 ($ million)
  • Global market: Year-over-year growth 2019 - 2024 (%)
  • Five forces analysis 2019 & 2024
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition - Five forces 2019
  • Other1 - Market share 2019-2024 (%)
  • Comparison by Other1
  • DA and levodopa-carbidopa - Market size and forecast 2019-2024 ($ million)
  • DA and levodopa-carbidopa - Year-over-year growth 2019-2024 (%)
  • MAO inhibitors - Market size and forecast 2019-2024 ($ million)
  • MAO inhibitors - Year-over-year growth 2019-2024 (%)
  • AChE inhibitors - Market size and forecast 2019-2024 ($ million)
  • AChE inhibitors - Year-over-year growth 2019-2024 (%)
  • Glutamate inhibitors - Market size and forecast 2019-2024 ($ million)
  • Glutamate inhibitors - Year-over-year growth 2019-2024 (%)
  • Others - Market size and forecast 2019-2024 ($ million)
  • Others - Year-over-year growth 2019-2024 (%)
  • Market opportunity by Other1
  • Customer landscape
  • Market share by geography 2019-2024 (%)
  • Geographic comparison
  • Europe - Market size and forecast 2019-2024 ($ million)
  • Europe - Year-over-year growth 2019-2024 (%)
  • North America - Market size and forecast 2019-2024 ($ million)
  • North America - Year-over-year growth 2019-2024 (%)
  • Asia - Market size and forecast 2019-2024 ($ million)
  • Asia - Year-over-year growth 2019-2024 (%)
  • ROW - Market size and forecast 2019-2024 ($ million)
  • ROW - Year-over-year growth 2019-2024 (%)
  • Key leading countries
  • Market opportunity by geography ($ million)
  • Impact of drivers and challenges
  • Vendor landscape
  • Landscape disruption
  • Industry risks
  • Vendors covered
  • Market positioning of vendors
  • AbbVie Inc. - Overview
  • AbbVie Inc. - Business segments
  • AbbVie Inc. - Key offerings
  • AbbVie Inc. - Key customers
  • AbbVie Inc. - Segment focus
  • Amneal Pharmaceuticals Inc. - Overview
  • Amneal Pharmaceuticals Inc. - Business segments
  • Amneal Pharmaceuticals Inc. - Key offerings
  • Amneal Pharmaceuticals Inc. - Key customers
  • Amneal Pharmaceuticals Inc. - Segment focus
  • Bausch Health Companies Inc. - Overview
  • Bausch Health Companies Inc. - Business segments
  • Bausch Health Companies Inc. - Key offerings
  • Bausch Health Companies Inc. - Key customers
  • Bausch Health Companies Inc. - Segment focus
  • Boehringer Ingelheim International GmbH - Overview
  • Boehringer Ingelheim International GmbH - Business segments
  • Boehringer Ingelheim International GmbH - Key offerings
  • Boehringer Ingelheim International GmbH - Key customers
  • Boehringer Ingelheim International GmbH - Segment focus
  • Eisai Co. Ltd. - Overview
  • Eisai Co. Ltd. - Business segments
  • Eisai Co. Ltd. - Key offerings
  • Eisai Co. Ltd. - Key customers
  • Eisai Co. Ltd. - Segment focus
  • GlaxoSmithKline Plc - Overview
  • GlaxoSmithKline Plc - Business segments
  • GlaxoSmithKline Plc - Key offerings
  • GlaxoSmithKline Plc - Key customers
  • GlaxoSmithKline Plc - Segment focus
  • Kyowa Kirin Co. Ltd. - Overview
  • Kyowa Kirin Co. Ltd. - Business segments
  • Kyowa Kirin Co. Ltd. - Key offerings
  • Kyowa Kirin Co. Ltd. - Key customers
  • Kyowa Kirin Co. Ltd. - Segment focus
  • Novartis AG - Overview
  • Novartis AG - Business segments
  • Novartis AG - Key offerings
  • Novartis AG - Key customers
  • Novartis AG - Segment focus
  • Teva Pharmaceutical Industries Ltd. - Overview
  • Teva Pharmaceutical Industries Ltd. - Business segments
  • Teva Pharmaceutical Industries Ltd. - Key offerings
  • Teva Pharmaceutical Industries Ltd. - Key customers
  • Teva Pharmaceutical Industries Ltd. - Segment focus
  • UCB SA - Overview
  • UCB SA - Product and service
  • UCB SA - Key offerings
  • UCB SA - Key customers
  • UCB SA - Segment focus
  • Currency conversion rates for US$
  • Research Methodology
  • Validation techniques employed for market sizing
  • Information sources
  • List of abbreviations
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie Inc.
  • Eisai Co. Ltd.
  • GlaxoSmithKline Plc
  • Kyowa Kirin Co. Ltd.
  • Novartis AG
  • UCB SA
The publisher recognizes the following companies as the key players in the global Parkinson's disease (PD) drugs market: AbbVie Inc., Amneal Pharmaceuticals Inc., Bausch Health Companies Inc., Boehringer Ingelheim International GmbH, Eisai Co. Ltd., GlaxoSmithKline Plc, Kyowa Kirin Co. Ltd., Novartis AG, Teva Pharmaceutical Industries Ltd., and UCB SA.

Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is rise in geriatric population.'

According to the report, one of the major drivers for this market is the new drug launches.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
  • AbbVie Inc.
  • Amneal Pharmaceuticals Inc.
  • Bausch Health Companies Inc.
  • Boehringer Ingelheim International GmbH
  • Eisai Co. Ltd.
  • GlaxoSmithKline Plc
  • Kyowa Kirin Co. Ltd.
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll